This novel monoclonal immunoglobulin, Pritoxaximab – formerly known as DXX00601 – represents considerable promise within the management of critical hemolytic condition (TRALI). Engineered by Bio-X, Pritoxaximab https://www.targetmol.com/compound/pritoxaximab